ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To

Field does not validate



インデックスリンク

インデックスツリー

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "5a6f0c44-0eb6-434a-ac22-239383af6a12"}, "_deposit": {"id": "4145", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "4145"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00004145"}, "item_10_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-12-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "418", "bibliographicPageStart": "411", "bibliographicVolumeNumber": "59", "bibliographic_titles": [{"bibliographic_title": "\u4fe1\u5dde\u533b\u5b66\u96d1\u8a8c"}]}]}, "item_10_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "A phase II study was conducted to evaluate the feasibility and efficacy of biweekly administration of paclitaxel and gemcitabine in patients with non-small cell lung cancer (NSCLC) who had been treated previously with platinum-based chemotherapy. Paclitaxel (150 mg/m2) and gemcitabine (1,000 mg/m2) were administered biweekly for at least 4 cycles. Thirty-one patients with a median age of 64 years (39-75 years) were enrolled in this study(stage IIIB/IV :11/20,PS 0/1/2:13/16/2).Partial response was observed in 7 cases (23%), and stable disease was seen in 18 cases (58%).Median survival time was 8.8 months with a one-year survival rate of 41.9 %.Hematological toxicities were mild and neutropenia of grade 3 or above was observed in one patient (3%). Non-hematological toxicities were also mild, including neurotoxicity (3%). Biweekly paclitaxel and gemcitabine combination chemotherapy was effective and tolerated well as second-line therapy against NSCLC.", "subitem_description_type": "Abstract"}]}, "item_10_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_10_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "\u4fe1\u5dde\u533b\u5b66\u96d1\u8a8c 59(6): 411-418(2011)", "subitem_description_type": "Other"}]}, "item_10_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "KOIZUMI, Tomonobu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html"}, {"subitem_link_text": "YASUO, Masanori", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ypnegpkh.html"}]}, "item_10_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u4fe1\u5dde\u533b\u5b66\u4f1a"}]}, "item_10_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_10_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0037-3826", "subitem_source_identifier_type": "ISSN"}]}, "item_10_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0037-3826", "subitem_source_identifier_type": "ISSN"}]}, "item_10_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00120815", "subitem_source_identifier_type": "NCID"}]}, "item_10_text_66": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "02"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "KOBAYASHI,  Takashi"}], "nameIdentifiers": [{"nameIdentifier": "9346", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KOIZUMI,  Tomonobu"}], "nameIdentifiers": [{"nameIdentifier": "9347", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YASUO,  Masanori"}], "nameIdentifiers": [{"nameIdentifier": "9348", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TSUSHIMA,  Kenji"}], "nameIdentifiers": [{"nameIdentifier": "9349", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAMAMOTO,  Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "9350", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KUBO,  Keishi"}], "nameIdentifiers": [{"nameIdentifier": "9351", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "filename": "Shinshu_med59-6-02.pdf", "filesize": [{"value": "231.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2319000, "url": {"label": "Shinshu_med59-6-02.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/4145/files/Shinshu_med59-6-02.pdf"}, "version_id": "c2d5f565-af9f-4d2f-9950-8a90144af227"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "second-line chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "platinum-resistant", "subitem_subject_scheme": "Other"}, {"subitem_subject": "non-small cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neurotoxicity", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy"}]}, "item_type_id": "10", "owner": "1", "path": ["461/463/464/487"], "permalink_uri": "http://hdl.handle.net/10091/13507", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2012-01-04"}, "publish_date": "2012-01-04", "publish_status": "0", "recid": "4145", "relation": {}, "relation_version_is_last": true, "title": ["Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy"], "weko_shared_id": null}
  1. 050 医学部, 大学院医学系研究科 (Faculty&Graduate School of Medicine)
  2. 0502 紀要・刊行物
  3. 05021 信州医学雑誌 (The Shinshu medical journal)
  4. Vol. 59 No. 6

Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

http://hdl.handle.net/10091/13507
b40fd3af-9740-4401-94e6-4cf68da8f057
プレビュー
名前 / ファイル ライセンス Actions
Shinshu_med59-6-02.pdf Shinshu_med59-6-02.pdf (231.9 kB)
item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2012-01-04
タイトル
タイトル Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
言語
言語 eng
キーワード
主題 second-line chemotherapy
キーワード
主題 platinum-resistant
キーワード
主題 non-small cell lung cancer
キーワード
主題 neurotoxicity
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
著者 KOBAYASHI, Takashi

× KOBAYASHI, Takashi

WEKO 9346

KOBAYASHI, Takashi

Search repository
KOIZUMI, Tomonobu

× KOIZUMI, Tomonobu

WEKO 9347

KOIZUMI, Tomonobu

Search repository
YASUO, Masanori

× YASUO, Masanori

WEKO 9348

YASUO, Masanori

Search repository
TSUSHIMA, Kenji

× TSUSHIMA, Kenji

WEKO 9349

TSUSHIMA, Kenji

Search repository
YAMAMOTO, Hiroshi

× YAMAMOTO, Hiroshi

WEKO 9350

YAMAMOTO, Hiroshi

Search repository
KUBO, Keishi

× KUBO, Keishi

WEKO 9351

KUBO, Keishi

Search repository
信州大学研究者総覧へのリンク
KOIZUMI, Tomonobu
http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html
信州大学研究者総覧へのリンク
YASUO, Masanori
http://soar-rd.shinshu-u.ac.jp/profile/ja.ypnegpkh.html
出版者
出版者 信州医学会
引用
内容記述タイプ Other
内容記述 信州医学雑誌 59(6): 411-418(2011)
書誌情報 信州医学雑誌

巻 59, 号 6, p. 411-418, 発行日 2011-12-10
抄録
内容記述タイプ Abstract
内容記述 A phase II study was conducted to evaluate the feasibility and efficacy of biweekly administration of paclitaxel and gemcitabine in patients with non-small cell lung cancer (NSCLC) who had been treated previously with platinum-based chemotherapy. Paclitaxel (150 mg/m2) and gemcitabine (1,000 mg/m2) were administered biweekly for at least 4 cycles. Thirty-one patients with a median age of 64 years (39-75 years) were enrolled in this study(stage IIIB/IV :11/20,PS 0/1/2:13/16/2).Partial response was observed in 7 cases (23%), and stable disease was seen in 18 cases (58%).Median survival time was 8.8 months with a one-year survival rate of 41.9 %.Hematological toxicities were mild and neutropenia of grade 3 or above was observed in one patient (3%). Non-hematological toxicities were also mild, including neurotoxicity (3%). Biweekly paclitaxel and gemcitabine combination chemotherapy was effective and tolerated well as second-line therapy against NSCLC.
資源タイプ(コンテンツの種類)
内容記述タイプ Other
内容記述 Article
ISSN
収録物識別子タイプ ISSN
収録物識別子 0037-3826
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00120815
著者版フラグ
値 publisher
Back
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:11:32.232945
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio